HNF4A and cancer: Given its use as an anti-diabtetogenic and hypolipidemic agent [42], [43], we treated D283MED cells with MEDICA 16 based on the position of HNF4A at a hub of direct and indirect relationships with critical molecules in transcription/translation and cancer biology (Figure 9 A).